Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation

Web Exclusives - Ovarian Cancer

With follow-up of >5 years, women with relapsed platinum-sensitive ovarian cancer and a BRCA mutation who participated in the multicenter phase 3 SOLO2 clinical trial lived >1 year longer if randomized to maintenance olaparib (Lynparza) compared with placebo, according to data released at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

At 5 years, 42% of patients in the olaparib group and 33% of patients in the placebo group were alive, reported SOLO2 lead investigator Andrés Poveda, MD, Medical Coordinator, Gynaecological Oncology Clinical Area, Valencian Oncology Institute, Initia Oncology, Hospital Quirónsalud, Valencia, Spain. “These results demonstrate that olaparib maintenance monotherapy not only delays disease progression but also improves overall survival in women with platinum-sensitive relapsed ovarian cancer and a BRCA mutation,” he said.

The final overall survival (OS) analysis of SOLO2 showed that with a median follow-up of 65 months, patients assigned to olaparib had a median OS of 51.7 months compared with 38.8 months for the patients assigned to placebo after platinum-based chemotherapy.

“A median OS improvement of nearly 13 months is impressive in ovarian cancer and brings a substantial benefit to our patients. With the addition of OS data, this study helps usher in a new era of personalized medicine for women with this difficult-to-treat cancer,” said Dr Poveda.

SOLO2 enrolled 295 patients with relapsed high-grade serous or endometrial platinum-sensitive relapsed ovarian cancer and a BRCA mutation. All received ≥2 previous lines of platinum-based chemotherapy and had responded to their most recent platinum regimen. They were randomized to olaparib (N = 196) 300 mg twice daily or placebo (N = 99), with treatment continuing until disease progression.

In the primary analysis of SOLO2, maintenance olaparib led to a significant improvement in progression-free survival of 13.6 months over placebo.

The OS improvement in the olaparib arm “is an impressive finding, particularly considering that 38% of placebo patients crossed over to receive subsequent PARP inhibitor therapy,” said Dr Poveda.

Among the 286 patients enrolled with a confirmed germline BRCA mutation using the Myriad BRCAnalysis test, the OS advantage with olaparib increased to 15 months—52.4 months in the olaparib arm versus 37.4 months in the placebo arm (hazard ratio [HR], 0.71; P = .0306).

At 5 years, 28% of olaparib patients versus 13% of placebo patients were alive and had not received subsequent therapy. Time to first subsequent therapy was 27.4 months in the olaparib arm versus 7.2 months in the placebo arm (HR, 0.37; P <.0001).

An exploratory analysis performed to adjust for impact of crossover to subsequent poly (ADP-ribose) polymerase (PARP) inhibitor therapy found an improvement of 16.3 months in OS with maintenance olaparib over placebo.

“This study confirms that the PARP inhibitor olaparib should be the standard maintenance therapy for patients with BRCA-related relapsed ovarian cancer responding to platinum-based chemotherapy—a significant advance for women with a cancer that has a historically poor prognosis,” commented ASCO Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD.

Related Items
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Web Exclusives published on September 15, 2020 in Ovarian Cancer
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Web Exclusives published on September 15, 2020 in Ovarian Cancer
PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer
Web Exclusives published on July 28, 2020 in Ovarian Cancer
Last modified: August 3, 2020